Complete Filing Data
Biohaven Ltd. reported Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents of $232.78 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Biohaven Ltd. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$738.8M | -$846.4M | -$408.2M | -$570.3M | -$213.8M | -$118.7M |
| Research And Development Expense | $635.1M | $795.9M | $373.3M | $437.1M | $181.5M | $98.5M |
| Operating Income Loss | -$745.4M | -$885.1M | -$436.1M | -$567.9M | -$218.9M | -$114.5M |
| Income Tax Expense Benefit | $1.4M | $735.0K | -$1.4M | $438.0K | $1.4M | $0.00 |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$737.4M | -$845.7M | -$409.6M | -$569.8M | -$212.4M | -$118.7M |
| General And Administrative Expense | $110.3M | $89.2M | $62.8M | $130.9M | $37.4M | $16.0M |
| Comprehensive Income Net Of Tax | -$730.6M | -$846.3M | -$408.5M | -$570.0M | -$213.8M | -$118.7M |
| Other Comprehensive Income Loss Net Of Tax | $8.3M | $144.0K | -$349.0K | $284.0K | $0.00 | $0.00 |
| Nonoperating Income Expense | $8.0M | $39.4M | $26.5M | -$1.9M | $6.5M | -$4.2M |
| Other Nonoperating Income Expense | $8.0M | $39.4M | $26.5M | -$1.9M | $1.2M | $0.00 |
| Income Taxes Receivable | $2.6M | $13.3M | $46.1M | $9.9M | ||
| Issuance Of Common Shares For Acquisition Of Research And Development Asset | 0.00 | 10.8M | 0.00 | |||
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -$8.0K | $66.0K | $148.0K | -$145.0K | $0.00 | $0.00 |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | -$3.0K | $78.0K | -$497.0K | $429.0K | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$173.4M | -$198.1M | -$221.7M | -$160.3M | -$319.8M | -$179.5M | -$102.6M | -$90.3M | -$70.5M | -$68.9M | -$203.3M | -$97.0M | -$54.4M | -$45.4M | -$62.1M |
| Research And Development Expense | $141.2M | $184.4M | $187.6M | $157.6M | $314.8M | $156.0M | $95.5M | $79.5M | $63.5M | $52.8M | $177.1M | $70.1M | $47.0M | ||
| Operating Income Loss | -$169.4M | -$211.7M | -$221.6M | -$178.2M | -$333.8M | -$183.2M | -$110.5M | -$94.0M | -$77.8M | -$67.6M | -$197.1M | -$89.8M | -$55.5M | ||
| Income Tax Expense Benefit | $221.0K | $261.0K | $609.0K | -$59.0K | $177.0K | $569.0K | -$3.3M | $2.2M | $939.0K | $1.2M | $6.1M | $7.3M | -$1.1M | ||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$173.2M | -$197.9M | -$221.1M | -$160.4M | -$319.6M | -$178.9M | -$105.9M | -$88.2M | -$69.6M | -$67.6M | -$197.2M | -$89.8M | -$55.5M | ||
| General And Administrative Expense | $28.2M | $27.3M | $34.0M | $20.6M | $19.0M | $27.3M | $15.0M | $14.5M | $14.3M | $14.8M | $20.0M | $19.7M | $8.5M | ||
| Comprehensive Income Net Of Tax | -$173.4M | -$198.2M | -$221.7M | -$160.1M | -$319.7M | -$179.5M | -$102.4M | -$90.5M | -$70.6M | -$68.9M | -$203.3M | -$97.0M | -$54.4M | ||
| Other Comprehensive Income Loss Net Of Tax | $39.0K | -$76.0K | -$6.0K | $218.0K | $28.0K | -$41.0K | $138.0K | -$146.0K | -$118.0K | $0.00 | $0.00 | $0.00 | |||
| Nonoperating Income Expense | -$3.8M | $13.8M | $493.0K | $17.8M | $14.2M | $4.3M | $4.7M | $5.8M | $8.2M | $0.00 | -$67.0K | -$4.0K | -$5.0K | ||
| Other Nonoperating Income Expense | $4.3M | $4.7M | $5.8M | $8.2M | $0.00 | -$67.0K | -$4.0K | -$5.0K | |||||||
| Income Taxes Receivable | $5.3M | $7.5M | $8.4M | $13.1M | $8.7M | $43.8M | |||||||||
| Issuance Of Common Shares For Acquisition Of Research And Development Asset | 0.00 | 10.3M | 0.00 | ||||||||||||
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | |||||||||||||||
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $52.1M | $423.4M | $428.0M | $538.8M | $34.7M | $16.8M | $14.5M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $232.8M | $102.5M | $252.1M | $242.6M | $77.1M | $83.5M | $9.9M |
| Cash And Cash Equivalents At Carrying Value | $230.0M | $99.1M | $248.4M | $204.9M | $76.1M | $82.5M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $130.2M | -$149.6M | $9.5M | $165.5M | -$6.4M | $73.6M | |
| Property Plant And Equipment Net | $16.0M | $17.3M | $17.2M | $17.5M | $13.0M | ||
| Other Liabilities Noncurrent | $4.6M | $4.7M | $2.2M | $2.4M | $2.6M | ||
| Other Assets Noncurrent | $47.4M | $39.5M | $33.8M | $37.5M | $14.4M | ||
| Other Assets Current | $2.2M | $3.1M | $12.1M | $19.3M | $2.1M | ||
| Liabilities Current | $115.9M | $154.2M | $55.4M | $90.0M | $41.9M | ||
| Liabilities And Stockholders Equity | $451.4M | $615.1M | $513.2M | $661.8M | $142.1M | ||
| Liabilities | $399.4M | $191.7M | $85.2M | $123.0M | $47.4M | ||
| Intangible Assets Net Excluding Goodwill | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M | ||
| Goodwill | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | ||
| Assets Current | $368.3M | $538.5M | $442.4M | $587.0M | $94.8M | ||
| Assets | $451.4M | $615.1M | $513.2M | $661.8M | $142.1M | ||
| Accrued Liabilities Current | $104.3M | $51.5M | $39.8M | $44.1M | $37.2M | ||
| Accounts Payable Current | $11.6M | $18.0M | $15.6M | $10.7M | $4.8M | ||
| Retained Earnings Accumulated Deficit | -$2.08B | -$1.35B | -$499.3M | -$91.1M | $0.00 | ||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Preferred Stock No Par Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Operating Lease Liability Noncurrent | $40.0M | $32.8M | $27.6M | $30.6M | $2.8M | ||
| Marketable Securities Current | $89.2M | $386.9M | $133.4M | $260.5M | $0.00 | ||
| Common Stock Value | $1.93B | $1.66B | $887.5M | $615.7M | $0.00 | ||
| Common Stock No Par Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $8.3M | $79.0K | -$65.0K | $284.0K | $0.00 | ||
| Cash Acquired From Acquisition | $0.00 | $391.0K | $0.00 | $0.00 | $1.9M | $0.00 | |
| Change In Restricted Cash Held On Behalf Of Former Parent Financing Activities | $0.00 | $0.00 | -$35.2M | $35.2M | $0.00 | ||
| Restricted Cash Current | $0.00 | $35.2M | $0.00 | $0.00 | |||
| Fair Value Adjustment Of Forward Contract And Derivative Liabilities | $0.00 | $102.5M | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | -$17.2M | $134.6M | $259.5M | $316.0M | $383.7M | $301.4M | $290.0M | $387.3M | $472.3M | $100.2M | $25.0M | $46.1M | $321.5M | $42.1M | $47.9M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $188.4M | $169.0M | $102.7M | $88.0M | $242.3M | $186.9M | $126.0M | $202.0M | $190.6M | $51.4M | $24.0M | $41.0M | $362.7M | ||
| Cash And Cash Equivalents At Carrying Value | $184.8M | $165.8M | $98.4M | $84.4M | $239.1M | $182.7M | $111.7M | $147.6M | $125.0M | $50.7M | $23.2M | $40.3M | $361.7M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $147.0K | -$65.2M | -$52.0M | -$36.0M | |||||||||||
| Property Plant And Equipment Net | $17.5M | $18.6M | $17.8M | $18.3M | $18.7M | $16.7M | $17.7M | $17.3M | $17.5M | $17.4M | |||||
| Other Liabilities Noncurrent | $4.6M | $4.6M | $4.6M | $4.6M | $4.3M | $3.4M | $2.3M | $2.5M | $2.5M | $7.0M | |||||
| Other Assets Noncurrent | $48.2M | $37.2M | $38.6M | $32.0M | $32.9M | $33.3M | $34.7M | $35.6M | $36.8M | $17.9M | |||||
| Other Assets Current | $8.4M | $8.4M | $3.6M | $1.2M | $7.3M | $10.7M | $22.9M | $22.3M | $24.7M | $12.0M | |||||
| Liabilities Current | $113.0M | $124.3M | $164.0M | $152.3M | $156.2M | $86.6M | $62.2M | $87.8M | $114.0M | $28.4M | |||||
| Liabilities And Stockholders Equity | $409.1M | $550.4M | $458.9M | $510.5M | $582.6M | $418.5M | $382.7M | $506.7M | $618.5M | $135.6M | |||||
| Liabilities | $426.3M | $415.8M | $199.5M | $194.5M | $198.9M | $117.1M | $92.7M | $119.5M | $146.3M | $35.4M | |||||
| Intangible Assets Net Excluding Goodwill | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M | $18.4M | |||||
| Goodwill | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | $1.4M | |||||
| Assets Current | $323.6M | $474.8M | $382.8M | $440.5M | $511.3M | $348.7M | $310.6M | $434.1M | $544.5M | $80.6M | |||||
| Assets | $409.1M | $550.4M | $458.9M | $510.5M | $582.6M | $418.5M | $382.7M | $506.7M | $618.5M | $135.6M | |||||
| Accrued Liabilities Current | $73.5M | $78.7M | $56.6M | $63.5M | $57.7M | $50.2M | $52.6M | $35.4M | $38.0M | $23.7M | |||||
| Accounts Payable Current | $17.5M | $19.6M | $19.1M | $19.7M | $17.3M | $36.4M | $9.5M | $12.0M | $14.5M | $4.7M | |||||
| Retained Earnings Accumulated Deficit | -$1.94B | -$1.77B | -$1.57B | -$1.16B | -$998.6M | -$678.8M | -$354.5M | -$252.0M | -$161.6M | ||||||
| Preferred Stock Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| Preferred Stock No Par Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| Operating Lease Liability Noncurrent | $40.4M | $29.8M | $30.8M | $25.3M | $26.2M | $27.1M | $28.3M | $29.1M | $29.8M | ||||||
| Marketable Securities Current | $75.4M | $239.2M | $224.3M | $294.4M | $197.8M | $100.7M | $128.9M | $187.5M | $263.0M | ||||||
| Common Stock Value | $1.74B | $1.74B | $1.69B | $1.38B | $1.30B | $911.0M | $618.8M | $617.5M | $616.2M | ||||||
| Common Stock No Par Value | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $36.0K | -$3.0K | $73.0K | $140.0K | -$78.0K | -$106.0K | $158.0K | $20.0K | $166.0K | ||||||
| Cash Acquired From Acquisition | $0.00 | $391.0K | $0.00 | ||||||||||||
| Change In Restricted Cash Held On Behalf Of Former Parent Financing Activities | $0.00 | $26.3M | $0.00 | ||||||||||||
| Restricted Cash Current | $28.0K | $40.4M | $61.5M | $0.00 | $0.00 | $0.00 | |||||||||
| Fair Value Adjustment Of Forward Contract And Derivative Liabilities |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $112.4M | $72.0M | $28.8M | $193.6M | $65.6M | $29.5M |
| Payments To Acquire Property Plant And Equipment | $715.0K | $4.0M | $3.0M | $6.1M | $938.0K | $1.1M |
| Net Cash Provided By Used In Operating Activities | -$609.4M | -$582.5M | -$331.7M | -$297.7M | -$145.8M | -$76.0M |
| Net Cash Provided By Used In Investing Activities | $300.6M | -$245.0M | $129.8M | -$304.8M | $944.0K | -$2.7M |
| Net Cash Provided By Used In Financing Activities | $439.1M | $677.8M | $211.9M | $767.6M | $138.4M | $152.2M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$3.5M | -$8.0M | -$27.2M | $41.3M | $9.2M | $2.4M |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $4.2M | $8.1M | -$7.4M | $6.8M | $9.8M | $14.9M |
| Increase Decrease In Accounts Payable | -$6.4M | $710.0K | $4.9M | $5.9M | $1.0M | $222.0K |
| Depreciation Depletion And Amortization | $9.9M | $7.9M | $6.9M | $1.4M | $1.4M | $72.0K |
| Payments To Acquire Available For Sale Securities Debt | $266.9M | $745.7M | $194.1M | $259.7M | $0.00 | $0.00 |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$3.0K | $75.0K | -$497.0K | $429.0K | $0.00 | $0.00 |
| Proceeds From Payments For Other Financing Activities | -$194.0K | $2.3M | $0.00 | $0.00 | $395.0K | $0.00 |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | $570.0M | $504.4M | $322.1M | $0.00 | $0.00 | |
| Proceeds From Issuance Of Common Stock | $189.2M | $666.2M | $243.2M | $283.8M | $0.00 | $0.00 |
| Payments Of Stock Issuance Costs | $1.7M | $2.2M | $800.0K | $1.0M | $0.00 | $0.00 |
| Proceeds From Sale Of Available For Sale Securities Debt | $0.00 | $0.00 | $4.9M | $0.00 | $0.00 | |
| Proceeds From Issuance Of Common Stock For License Agreements | $4.8M | $71.6M | $21.8M | $0.00 | $0.00 | |
| Proceeds From Contributions From Affiliates | $0.00 | $0.00 | $449.1M | $138.1M | $92.2M | |
| Proceeds From Acquisition Of Research And Development Asset | $10.8M | $0.00 | $93.7M | $0.00 | $0.00 | |
| Payments To Acquire In Process Research And Development | $0.00 | $0.00 | $35.0M | $0.00 | $0.00 | |
| Proceeds From Stock Options Exercised |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Based Compensation | $21.5M | $20.8M | $53.1M | $12.2M | $12.2M | $34.9M | $4.5M | $4.7M | $3.8M | $17.0M | $40.1M | $15.4M |
| Payments To Acquire Property Plant And Equipment | $461.0K | $440.0K | $735.0K | $246.0K | ||||||||
| Net Cash Provided By Used In Operating Activities | -$165.1M | -$102.6M | -$77.6M | -$58.8M | ||||||||
| Net Cash Provided By Used In Investing Activities | $164.9M | $34.0M | -$1.1M | -$246.0K | ||||||||
| Net Cash Provided By Used In Financing Activities | $369.0K | $3.4M | $26.7M | $23.0M | ||||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $7.2M | $2.6M | $279.0K | -$3.2M | ||||||||
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $2.8M | $9.2M | -$14.3M | -$8.9M | ||||||||
| Increase Decrease In Accounts Payable | $91.0K | $19.1M | $3.8M | $1.9M | ||||||||
| Depreciation Depletion And Amortization | $2.2M | $1.4M | $1.6M | $250.0K | ||||||||
| Payments To Acquire Available For Sale Securities Debt | $44.7M | $47.1M | $29.8M | $0.00 | ||||||||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $23.0K | -$6.0K | $15.0K | $0.00 | ||||||||
| Proceeds From Payments For Other Financing Activities | $0.00 | $1.2M | $0.00 | $0.00 | ||||||||
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | $210.0M | $81.2M | $27.0M | |||||||||
| Proceeds From Issuance Of Common Stock | ||||||||||||
| Payments Of Stock Issuance Costs | ||||||||||||
| Proceeds From Sale Of Available For Sale Securities Debt | $0.00 | $0.00 | $0.00 | $0.00 | $2.5M | $2.5M | ||||||
| Proceeds From Issuance Of Common Stock For License Agreements | $4.8M | $5.6M | ||||||||||
| Proceeds From Contributions From Affiliates | $0.00 | $23.0M | ||||||||||
| Proceeds From Acquisition Of Research And Development Asset | ||||||||||||
| Payments To Acquire In Process Research And Development | ||||||||||||
| Proceeds From Stock Options Exercised | $369.0K | $2.2M | $332.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 107.6M | 91.2M | 71.2M | 44.7M | 39.4M | 39.4M |
| Weighted Average Number Of Diluted Shares Outstanding | 107.6M | 91.2M | 71.2M | 44.7M | 39.4M | 39.4M |
| Earnings Per Share Diluted | $-6.86 | $-9.28 | $-5.73 | $-12.75 | $-5.43 | $-3.01 |
| Earnings Per Share Basic | $-6.86 | $-9.28 | $-5.73 | $-12.75 | $-5.43 | $-3.01 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | |
| Common Stock Shares Outstanding | 132.8M | 101.2M | 81.1M | 68.2M | 0.00 | |
| Common Stock Shares Issued | 132.8M | 101.2M | 81.1M | 68.2M | 0.00 | |
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 200.0M | 0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 105.8M | 102.4M | 101.9M | 94.4M | 87.8M | 81.6M | 68.3M | 68.2M | 68.2M | 39.4M | 39.4M | 39.4M | 39.4M |
| Weighted Average Number Of Diluted Shares Outstanding | 105.8M | 102.4M | 101.9M | 94.4M | 87.8M | 81.6M | 68.3M | 68.2M | 68.2M | 39.4M | 39.4M | 39.4M | 39.4M |
| Earnings Per Share Diluted | $-1.64 | $-1.94 | $-2.17 | $-1.70 | $-3.64 | $-2.20 | $-1.50 | $-1.32 | $-1.03 | $-1.75 | $-5.16 | $-2.46 | $-1.38 |
| Earnings Per Share Basic | $-1.64 | $-1.94 | $-2.17 | $-1.70 | $-3.64 | $-2.20 | $-1.50 | $-1.32 | $-1.03 | $-1.75 | $-5.16 | $-2.46 | $-1.38 |
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Preferred Stock Shares Authorized | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | 10.0M | ||||
| Common Stock Shares Outstanding | 105.8M | 105.8M | 102.1M | 94.9M | 92.3M | 81.8M | 68.4M | 68.3M | 68.2M | ||||
| Common Stock Shares Issued | 105.8M | 105.8M | 102.1M | 94.9M | 92.3M | 81.8M | 68.4M | 68.3M | 68.2M | ||||
| Common Stock Shares Authorized | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M | 200.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Costs And Expenses | $745.4M | $885.1M | $436.1M | $567.9M | $218.9M | |
| Other Noncash Income Expense | -$174.0K | $11.7M | $5.7M | -$726.0K | $3.4M | $0.00 |
| Issuance Of Stock And Warrants For Services Or Claims | $0.00 | $3.3M | $0.00 | $1.8M | $7.9M | $0.00 |
| Prepaid Expense Current | $47.0M | $49.4M | $35.2M | $20.9M | $6.7M | |
| Additional Paid In Capital | $194.0M | $112.4M | $39.8M | $13.9M | $0.00 | |
| Stock Issued During Period Value New Issues | $188.7M | $664.0M | $21.8M | $282.8M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Costs And Expenses | $169.4M | $211.7M | $221.6M | $178.2M | $333.8M | $183.2M | $110.5M | $94.0M | $77.8M | $67.6M | $197.1M | $89.8M | $55.5M |
| Other Noncash Income Expense | $2.8M | $1.1M | $1.7M | $250.0K | |||||||||
| Issuance Of Stock And Warrants For Services Or Claims | $5.6M | $0.00 | $1.8M | ||||||||||
| Prepaid Expense Current | $55.0M | $61.5M | $56.4M | $55.2M | $59.5M | $46.2M | $33.9M | $27.7M | $26.4M | $17.9M | |||
| Additional Paid In Capital | $178.0M | $157.0M | $137.5M | $93.0M | $83.8M | $69.4M | $25.6M | $21.7M | $17.5M | ||||
| Stock Issued During Period Value New Issues |
Most recent annual filing with the SEC: March 2, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.